Mediware Information Systems
) has strengthened its position in the blood management solutions
industry with the acquisition of Indianapolis based Strategic
Healthcare Group, a leading provider of blood management
consulting, education and informatics solutions. The company had
announced its decision to acquire Strategic Healthcare on August 6,
Strategic Healthcare's portfolio includes the Strategic blood
management system and a robust informatics suite catering to
learning management, knowledge management and data management.
These include the BloodStat Multidimensional Analytics database,
the Blood Management University, and Blood Management Exchange
Low global penetration and demand outstripping supply provide a
positive long-term thesis for investing in the blood processing and
supply chain management industry. Viewing the huge potential in the
blood management business, several players have chosen the
acquisition route to diversify their offerings.
) last month acquired
) blood collection, filtration and processing product lines for
$551 million. The company also announced the acquisition of Hemerus
Medical, a Minnesota-based company that develops technologies for
the collection of whole blood, and processing and storage of blood
This is not the first deal of Mediware in the field of
performance management and analytics. The company acquired Insight
technology in 2009 and has integrated the Insight performance
management technology with its core software products - HCLL
Transfusion for hospital blood banks and the LifeTrak software for
The InSight software has been licensed by major blood centers
including the BloodCenter of Wisconsin and Kansas City Community
Blood Center. In addition, several hospitals have also licensed the
software, the latest being Plymouth based Jordan Hospital.
Mediware's acquisition strategy targets businesses which are a
strategic fit to expand its product offerings. These areas are
leveraging expertise in alternate care settings, building on
performance management, focus on software and advanced
In January 2012, the company acquired St. Louis-based Transtem,
a provider of software that manages the collection and
transplantation of adult stem cells in cellular-based therapies and
medical research. This was followed by the acquisition of Cyto
Management System in April that strengthened Mediware's portfolio
with a chemotherapy management solution.
Mediware retains a Zacks #3 Rank (Hold) in the short term.
HAEMONETICS CP (HAE): Free Stock Analysis
(MEDW): ETF Research Reports
PALL CORP (PLL): Free Stock Analysis Report
To read this article on Zacks.com click here.